Gerald M. Lieberman
CIK: 0001234346
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Jun 5, 2026TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Exercise(M)Direct14.5K shares- - May 28, 2026TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Award(A)DirectRestricted Share Units
7.2K shares- - Jan 1, 2026ENTX
Entera Bio Ltd.
Award(A)Direct38.3K shares- - Jun 6, 2025TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Exercise(M)Direct9.6K shares- - Jun 5, 2025TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Award(A)DirectRestricted Share Units
14.5K shares- - Apr 1, 2025ENTX
Entera Bio Ltd.
Exercise(M)Direct24K shares at avg. $1.00$24K - Jan 15, 2025ENTX
Entera Bio Ltd.
Award(A)Direct10.7K shares- - Oct 2, 2024ENTX
Entera Bio Ltd.
Award(A)Direct11.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 5, 2026 |  TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | Exercise(M) | 14,492 | - | $0 | Direct |
| May 28, 2026 | TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | Award(A) Restricted Share Units | 7,242 | - | - | Direct |
| Jan 1, 2026 |  ENTX Entera Bio Ltd. | Award(A) | 38,294 | - | $0 | Direct |
| Jun 6, 2025 | TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | Exercise(M) | 9,632 | - | - | Direct |
| Jun 5, 2025 | TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | Award(A) Restricted Share Units | 14,492 | - | - | Direct |
| Apr 1, 2025 | ENTX Entera Bio Ltd. | Exercise(M) | 23,952 | $1.00 | $23,952 | Direct |
| Jan 15, 2025 | ENTX Entera Bio Ltd. | Award(A) | 10,717 | - | $0 | Direct |
| Oct 2, 2024 | ENTX Entera Bio Ltd. | Award(A) | 11,269 | - | $0 | Direct |
1-8 of 8 transactions
About LIEBERMAN GERALD M
LIEBERMAN GERALD M (SEC CIK 0001234346) files insider reports with the SEC as Director of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) and Director of Entera Bio Ltd. (ENTX).
Signal8 holds 7 ownership filings by LIEBERMAN GERALD M, all Form 4s, filed between Oct 4, 2024 and Jun 8, 2026. Those filings report 8 transactions, from Oct 2, 2024 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on LIEBERMAN GERALD M's filings is in TEL AVIV.
Recent filings by LIEBERMAN GERALD M
- Jun 5, 2026: Option exercise of TEVA shares (Form 4, code M).
- May 28, 2026: Grant or award of TEVA derivative securities (Form 4, code A).
- Jan 1, 2026: Grant or award of ENTX shares (Form 4, code A).
- Jun 6, 2025: Option exercise of TEVA shares (Form 4, code M).
- Jun 5, 2025: Grant or award of TEVA derivative securities (Form 4, code A).
Other insiders filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
- Bergwerk Dov, Interim Cheif Legal Officer
- Savage Brian, Interim Chief Legal Officer
- MIGNONE ROBERTO, Director
- Weiss Amir, Chief Accounting Officer
- Satchi-Fainaro Ronit, Director
- Lippman Evan, EVP, Business Development